Announced Tue, 4 Aug · 14:03 IST
Morepen Q1 FY27 revenue up 34%, PAT jumps 394% YoY; CDMO goes full scale
Revenue Growth 20pctPat Growth 25pctEbitda Margin ExpansionResults View source PDFExplain this filing
MOREPENLAB · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Price reaction · full curve 14 horizons · vs prior close
+33.6%1-day move
₹57.40
prior close
₹68.18
base price
In-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
+1.5+1.5+1.5+1.5+33.6+38.6+39.4+39.5+33.8+41.6————
Up moveDown movePending
AI summary
Morepen Labs posted its highest-ever quarterly revenue of Rs. 575.31 Cr in Q1 FY27, up 34% YoY. EBITDA surged 207% YoY to Rs. 87.72 Cr with margin improving to 15.25% from 6.65%. PAT jumped 394% YoY to Rs. 56.35 Cr. Exports grew 111% and API exports rose 42%. The Rs. 825 Cr CDMO mandate entered full scale commercialization with Rs. 58 Cr dispatches already done. Medical devices grew 19%. Four consecutive USFDA inspections had zero observations.
Likely market impact
Strong across-the-board growth with massive PAT jump signals improving profitability and successful CDMO transition, likely positive for stock sentiment.